|Bid||0.00 x 1000|
|Ask||114.42 x 3100|
|Day's Range||114.05 - 115.92|
|52 Week Range||101.36 - 132.13|
|Beta (3Y Monthly)||0.16|
|PE Ratio (TTM)||13.88|
|Forward Dividend & Yield||2.58 (2.24%)|
|1y Target Est||N/A|
Eli Lilly & Co. said Wednesday that it will create 100 new jobs in Indianapolis as it invests $400 million in its manufacturing facilities at its Lilly Technology Center campus. The drug maker said its plans are a result of increased demand for its medicines and for the production of additional capacity for future medicines, and are helped by having more capital available as a result of tax reform. "These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations," said Myles O'Neill, president of manufacturing operations. "All of these projects support Lilly's investment in next generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics." The stock, which was still inactive in premarket trading, has slipped 0.5% year to date, while the SPDR Health Care Select Sector ETF has climbed 13.0% and the S&P 500 has advanced 24.5%.
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes. The drug, empagliflozin, was approved in 2014 in doses of 10 mg and 20 mg to help lower blood sugar levels in patients with type 2 diabetes and is marketed as Jardiance.
The fate of a local company’s treatment for attention deficit hyperactivity disorder is now in regulators’ hands. Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) has submitted its application to the Food and Drug Administration to take its ADHD drug to market, the company announced Monday. Supernus has put the product candidate through a handful of phase 3 clinical trials, to study its ability to reduce ADHD symptoms.
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Let's check out the charts and technical indicators to see if these two investment approaches are pointing in the same direction. In the daily bar chart of LLY, below, we can see that prices have moved sideways since the beginning of July with buyers coming in around $105 while rallies above $115 plus have failed so far. Trading volume has been featureless since April but the daily On-Balance-Volume (OBV) line has been flat/steady since April.
Nektar's (NKTR) reports encouraging third-quarter results. The company continues to progress with its pipeline candidates. However, the timeline for its pain drug NKTR-181's approval remains uncertain.
Pharmaceutical stocks rose a single-digit percentage in the first 10 months of 2019, well below their gain for 2018. Still, there are standout companies among the industry group.
Botox, Juveederm fillers, Vraylar drive Allergan's (AGN) third-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.
Chairman and CEO David Ricks made his first open-market purchase of stock late in October. The drug giant’s shares are in the red for the year while the S&P 500 is up double digits.
I always keep tabs on IPO stocks, as I'm a big believer in investing early, but I'll be the first to tell you that it's not always easy.If you're looking for large, long-term gains - and who isn't? - investing early is necessary. One example you probably know is Facebook (NASDAQ:FB). If you'd invested five years ago, you'd be richer today than if you'd just invested this year.But on the road to greatness, Facebook hit its share of roadblocks. In fact, the stock went absolutely nowhere for over a year after its IPO in 2012.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe market is full of stories like that. And IPO stocks don't always go on to do great things. Some of the most anticipated IPOs fizzle out before they even begin, as we recently saw with the whole WeWork debacle. * 7 Stocks to Buy in November In the space of just one month, the coworking office space company filed for an IPO, saw potential creditors flee once they got a look at its financials, yanked the IPO entirely, and ultimately fired its scandalous CEO, Adam Neumann. WeWork was once privately valued at $47 billion, but now that seems to have gone up in smoke.One big problem here is that once WeWork got into the spotlight, the hype - and the valuation - got out of control. I've seen it many times before, but sooner or later, the honeymoon ends and reality sets in. Put These Two IPO Stocks On Your Watch ListRight now, the best-performing IPO stocks are also the least talked-about, which is pretty telling. A couple stand out to me right now. They might not have a cool enough story to get on TV, but you'll definitely want to put them on your watch list all the same.InMode (NASDAQ:INMD) is a medical device company based in Israel. Specifically, its products are used in minimally invasive surgical and aesthetic procedures in the fields of dermatology, cellulite removal, and gynecology. It's a $1 billion company by market cap, was founded in 2008, and has been profitable for years. Financial buzz puts the sector InMode is going after, medical aesthetics, at $22.2 billion in five years.INMD stock is up 133% since its IPO this August. Even better, its sales are on a steady climb, too - from $53 million in 2017 to $187 million projected for 2020. That would be 253% sales growth in just three yearsThe other promising, under-the-radar IPO is NextCure (NASDAQ:NXTC). It's a clinical stage biotech focused on cancer treatments. The company is pretty small at a market cap of less than $600 million, but it has a deal with drug giant Eli Lilly (NYSE:LLY) that could result in up to $1.4 billion in milestone payments. The stock is up 30% since its IPO this May. Given the lucrative deal with Big Pharma, I wouldn't be surprised to see much better gains down the road.If you've never heard of either of these IPO stocks before, I wouldn't be surprised. They've been neglected by the media "hype machine"… and that's promising. It tells me that there's still a lot of potential for future gains - gains that these companies can earn the old fashioned way: by selling more product and delivering shareholder value, year after year.I'll be keeping an eye out for that. You should, too.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post WeWork IPO was a Failure a These 2 IPO Stocks are Surging appeared first on InvestorPlace.